Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26455611 | 0.93 | MAPT (0.32) | MAPTHPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL26455616 | 0.91 | MAPT (0.32) | MAPTHPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL13044264 | 0.87 | — | — | |
| SCHEMBL8949497 | 0.84 | MAPT (0.36) | MAPTHPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL20199371 | 0.78 | MAPT (0.38) | MAPT | |
| SCHEMBL13293940 | 0.77 | FDPS (0.31) | — | |
| SCHEMBL12437180 | 0.77 | CA12 (0.34) | MAPTALDH1A1 | |
| SCHEMBL12669645 | 0.76 | CYP1A2 (0.33) | MAPTHPGDMAPK1KDM4EALDH1A1 | |
| Trolamine SCHEMBL23040981 | 0.76 | GPR84 (0.47) | ALDH1A1HSD17B10 | |
| SCHEMBL22763803 | 0.75 | LCK (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9504637-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160106648-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-9248086-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150174026-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8932370-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140326269-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8758451-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140013520-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8444715-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120272990-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8187340-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8008335-B2 | Indole and benzimidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008335-B2 | Indole and benzimidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110154583-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-12-09 | — | — | US | disclosed |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-12-09 | — | — | US | disclosed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | CHIRON CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | CHIRON CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120272990-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | MAPT 2715/4885HPGD 738/4885MAPK1 3478/4885 |
| US-20110154583-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | MAPT 2715/4885HPGD 738/4885MAPK1 3478/4885 |
| US-20160106648-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | MAPT 2715/4885HPGD 738/4885MAPK1 3478/4885 |
| US-20140013520-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | MAPT 2715/4885HPGD 738/4885MAPK1 3478/4885 |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | IDO1, IDO2, AADAC | MAPT 1798/4885HPGD 686/4885MAPK1 4569/4885 |
| US-20150174026-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | MAPT 2715/4885HPGD 738/4885MAPK1 3478/4885 |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | HSP90AA1, HSP90AB1, HSP90B1 | MAPT 3220/4885HPGD 1166/4885MAPK1 3411/4885 |
| US-20140326269-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | MAPT 2715/4885HPGD 738/4885MAPK1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.